二甲双胍对初诊2型糖尿病患者代谢指标影响的研究进展

摘要
图/表
参考文献(32)
相关文章 (8)

全文: PDF (740 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要二甲双胍降糖已有将近60年的历史，多个糖尿病研究学会认为二甲双胍能够作为临床上2型糖尿病治疗的一线用药。因此，在给予生活方式管理的基础上，应用二甲双胍单药治疗是多数初诊2型糖尿病患者治疗的首选方案。近年来，二甲双胍除降糖以外的其他作用越来越被重视，已有很多研究证明二甲双胍对血压、血脂代谢及体重等指标也存在调控作用。本文在给予规范的生活方式（饮食和运动）的干预下，将二甲双胍对初诊2型糖尿病患者的相关代谢指标的影响作一综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	鹿继璇詹晓蓉▲

关键词 ：二甲双胍, 代谢指标, 初诊, 2型糖尿病

Abstract：Metformin has been used as a hypoglycemic agent for nearly 60 years. A number of Diabetes Research Institute believes that Metformin can be used as first-line drugs in clinical treatment of type 2 diabetes. Therefore, based on the given lifestyle management, Metformin monotherapy is the most preferred regimen in the treatment of newly diagnosed type 2 diabetes patients. In recent years, Metformin has been paid more and more attention in addition to its hypoglycemic effects. Many studies have shown that Metformin also plays a regulatory role in blood pressure, lipids metabolism, body weight and so on. This article reviews the effects of Metformin on related metabolic parameters in patients with newly diagnosed type 2 diabetes mellitus under the influence of standardized lifestyle（diet and exercise）.

Key words： Metformin Metabolic markers Preliminary diagnosis Type 2 diabetes mellitus

通讯作者: ▲通讯作者

引用本文:

鹿继璇詹晓蓉▲. 二甲双胍对初诊2型糖尿病患者代谢指标影响的研究进展[J]. 中国医药导报, 2018, 15(8): 32-34,39.
LU Jixuan ZHAN Xiaorong▲. Research progress of Metformin on metabolic markers in newly diagnosed type 2 diabetic patients. 中国医药导报, 2018, 15(8): 32-34,39.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I8/32

[1] Rena G，Hardie DG，Pearson ER. The mechanisms of action of metformin [J]. Diabetologia，2017，60（9）：1577-1585.
[2] Wang YW，He SJ，Feng X，et al. Metformin：a review of its potential indications [J]. Drug Des Devel Ther，2017，11：2421-2429.
[3] Singh N，Madhu M，Vanamail P，et al. Efficacy of metformin in improving glycaemic control & perinatal outcome in gestational diabetes mellitus：A non-randomized study [J]. Indian J Med Res，2017，145（5）：623-628.
[4] Luizon MR，Eckalbar WL，Wang Y，et al. Genomic Characterization of Metformin Hepatic Response [J]. PLoS Genet，2016，12（11）：e1006449.
[5] An H，He L. Current understanding of metformin effect on the control of hyperglycemia in diabetes [J]. J Endocrinol，2016，228（3）：R97.
[6] Zheng J，Woo S L，Hu X，et al. Metformin and metabolic diseases：a focus on hepatic aspects [J]. Front Med，2015， 9（2）：173-186.
[7] Hannah R. Bridges，Andrew J.Y. Jones，Michael N. Pollak，et al. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria [J]. Biochem J，2014， 462（Pt 3）：475-487.
[8] Kinaan M，Ding H，Triggle CR. Metformin：An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium [J]. Med Princ Pract，2015，24（5）：401-415.
[9] Madiraju AK，Erion DM，Rahimi Y，et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase [J]. Nature，2014，510（7506）：542-546.
[10] Ross FA，Mackintosh C，Hardie DG. AMP-activated protein kinase：a cellular energy sensor that comes in twelve flavours [J]. FEBS J，2016，283（16）：2987-3001.
[11] Zhang CS，Li M，Ma T，et al. Metformin Activates AMPK through the Lysosomal Pathway [J]. Cell Metab，2016，24（4）：521-522.
[12] Pavlidou T，Rosina M，Fuoco C，et al. Regulation of myoblast differentiation by metabolic perturbations induced by metformin [J]. PLoS One，2017，12（8）：e0182475.
[13] Nostell KEA，Lindåse SS，Bröjer JT. Blood pressure in Warmblood horses before and during a euglycemic-hyperinsulinemic clamp [J]. Acta Vet Scand，2016，58（1）：65.
[14] Patel JP，Lee EH，Mena CI，et al. Effects of metformin on endothelial health and erectile dysfunction [J]. Transl Androl Urol，2017，6（3）：556-565.
[15] Majithiya JB，Balaraman R. Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats [J]. Life Sci，2006，78（22）：2615-2624.
[16] Petersen JS，Andersen D，Muntzel MS，et al. Intracerebr-oventricular metformin attenuates salt-induced hypertension in spontaneously hypertensive rats [J]. Am J Hypertens，2001，14（11 Pt 1）：1116-1122.
[17] Lee JM，Peuler JD. A possible indirect sympathomimetic action of metformin in the arterial vessel wall of spontanously hypertensive rats [J]. Life Sci，2001，69（9）：1085-1092.
[18] Thomopoulos C，Katsimagklis G，Makris T. Metformin and blood pressure lowering：a questioned association [J]. J Hypertens. 2017，35（1）：27-28.
[19] Valencia WM，Palacio A，Tamariz L，et al. Metformin and ageing：improving ageing outcomes beyond glycaemic control [J]. Diabetologia，2017，60（9）：1630-1638.
[20] Zahra K，Abdolkarim M，Anvarsadat K，et al. The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes：HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin [J]. PloS One，2016，11（3）：e0151543.
[21] Patel VI，Patel KP，Makadia MG，et al. Levels of Apolipoprotein A1，B100 and Lipoprotein （a）in Controlled and Uncontrolled Diabetic Patients and in Non-Diabetic Healthy People [J]. J Clin Diagn Res，2017，11（2）：BC01-BC05.
[22] Tani S，Yagi T，Atsumi W，et al. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus：a cross-sectional study [J]. Cardiovasc Diabetol，2017，16（1）：123.
[23] Zheng S，Zhou H，Han T，et al. Clinical characteristics and beta cell function in Chinese patients with newly diagnosed type 2 diabetes mellitus with different levels of serum triglyceride [J]. BMC Endocr Disord，2015，15（1）：21.
[24] Tomkin GH，Owens D. Diabetes and dyslipidemia：characterizing lipoprotein metabolism [J]. Diabetes Metab Syndr Obes，2017，10：333-343.
[25] Ye W，Ramos E H，Wong B C，et al. Beneficial Effects of Metformin and/or Salicylate on Palmitate- or TNF-αInduced Neuroinflammatory Marker and Neuropeptide Gene Regulation in Immortalized NPY/AgRP Neurons [J]. PloS One，2016，11（11）：e0166973.
[26] Li W，Yang X，Tao Z，et al. TNF stimulates endothelial palmitic acid transcytosis and promotes insulin resistance [J]. Scientific Rep，2017，7：44659.
[27] Seifarth C，Schehler B，Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity [J]. Exp Clin Endocrinol Diabetes，2013，121（1）：27-31.
[28] Malin SK，Nightingale J，Choi SE，et al. Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults [J]. Obesity，2013，21（1）：93-100.
[29] Hundal RS，Inzucchi SE. Metformin：new understandings，new uses [J]. Drugs，2003，63（18）：1879-1894.
[30] Troncone M，Cargnelli SM，Villani LA，et al. Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer（NSCLC）to cytotoxic therapy：translational biology and rationale for current clinical trials [J]. Oncotarget，2017，8（34）：57733-57754.
[31] Elarabey AA. New insight for metformin against bladder cancer [J].Genes Environ，2017，39（1）：13.
[32] Esmaeilzadeh S，Gholinezhadchari M，Ghadimi R. The Effect of Metformin Treatment on the Serum Levels of Homocysteine，Folic Acid，and Vitamin B12 in Patients with Polycystic Ovary Syndrome [J]. J Hum Reprod Sci，2017， 10（2）：95-101.